Healthcare / BiotechnologyTSXV
$0.62
+0.02 (+3.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-3.9M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$32M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1292.9%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-7.4M · FCF $-6.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-7.4M | $-7.4M | $-3.1M | $-5.1M | $-3.9M |
| EBITDA | $-7.4M | $-7.4M | $-3.6M | $-5.2M | $-3.9M |
| EPS | -0.15 | -0.15 | -0.07 | -0.13 | -0.16 |
| Balance Sheet | |||||
| Current Ratio | 0.82 | 0.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.0M | $-6.0M | $-3.9M | $-3.2M | $-2.1M |
| Returns | |||||
| ROE | -1292.9% | -1292.9% | -91.8% | -91.6% | -65.6% |
| Valuation | |||||
| P/B | 52.44 | 52.44 | 7.95 | 5.02 | 2.54 |
| Growth & Yield | |||||
| EPS Growth | -114.3% | -114.3% | 46.2% | 18.8% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → -0.15
Residual
-11.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.